Soligenix Inc. has published positive results from its comparability study evaluating HyBryte versus Valchlor for the treatment of cutaneous T-cell lymphoma in Oncology and Therapy, revealing significantly better efficacy and safety outcomes for its investigational therapy. After 12 weeks of treatment, 60% of HyBryte-treated patients achieved treatment success compared to just 20% for Valchlor-treated patients, with HyBryte also showing greater average improvement in clinical response.
The study results are particularly important because HyBryte demonstrated no treatment-related adverse events, while Valchlor patients experienced multiple adverse reactions. This safety profile difference could make HyBryte a more attractive treatment option for patients with early-stage CTCL who require long-term management of their condition. The findings support HyBryte's potential as a well-tolerated therapy that doesn't compromise on efficacy.
Cutaneous T-cell lymphoma is a rare form of non-Hodgkin lymphoma that primarily affects the skin, and current treatments often come with significant side effects that can impact patients' quality of life. The superior safety profile shown by HyBryte in this study addresses a critical unmet need in CTCL treatment, where balancing efficacy with tolerability remains a significant challenge for clinicians and patients alike.
Soligenix is developing HyBryte as a novel photodynamic therapy that utilizes safe visible light for CTCL treatment. The company's Specialized BioTherapeutics business segment is moving toward potential commercialization of HyBryte following successful completion of the second Phase 3 study. Regulatory approvals will be sought to support potential commercialization worldwide, which could significantly expand treatment options for CTCL patients globally.
The full study details are available in the Oncology and Therapy publication, and additional information about the company's development programs can be found through their corporate communications. The company's broader research portfolio includes expansion of synthetic hypericin into psoriasis treatment and development of vaccine candidates for various infectious diseases through its Public Health Solutions business segment, which has received government funding from agencies including the National Institute of Allergy and Infectious Diseases.
